KMC Speciality Hospitals – 250 Beds, 1,119 Crore Market Cap, and Still Charging Like Apollo Jr.
1. At a Glance
KMC Speciality Hospitals in Trichy may not have the nationwide glamour of Apollo, but with 250 beds and a shiny new 200-bed mother & child block, it is clearly punching above its weight. The market has given it a ₹1,119 Cr cap, a P/E of 47.7, and no dividend in sight. Basically, this is a Tier-2 city hospital priced like it’s running AI-powered robotic surgeries on Mars.
2. Introduction
Founded in 1982, KMC Speciality is a proud part of the Kauvery Group—a 2,250-bed hospital empire across 12 locations in South India. KMC’s flagship in Trichy is their cash cow, serving middle-class Tamil Nadu families with everything from heart surgeries to hairline fractures.
The group is known for:
1 lakh IP patients a year, 10 lakh OP patients, and 600+ transplants.
Being the go-to for joint replacements and kidney procedures in the region.
Becoming one of those family names where the discharge summary is as important as the wedding invitation.
But don’t get carried away. KMC has just one main hospital (250 beds) plus the new 200-bed mother-and-child care facility. Expansion is funded by debt (borrowings rose from ₹50 Cr in FY23 to ₹89 Cr in FY25). The hospital is busy, but the balance sheet has a mild fever.
Question: Can KMC ride on Kauvery’s brand halo, or will it remain the little brother always compared to Apollo and Max?
3. Business Model – WTF Do They Even Do?
Simple: Admit patients, treat them, bill them, repeat. But in detail:
Mother & Child Care (26%) – The newly expanded facility; pediatrics, neonatology, obstetrics.
Neuro Science (17%) – Brain & spine work. From headaches to full-scale neurosurgery.
Gastro Science (12%) – Stomach to liver, all included.
Critical Care (9%) – ICU beds always humming.
General Medicine (8%) – Old-school OPD and consultations.
Plastic Surgery (7%) – Not just cosmetic, but also burns and trauma.
Renal Science (6%) – Kidney care, dialysis.
Orthopaedics (6%) – Joint replacements and fractures.
Others (11%) – Basically, everything else under the sun.
Payor Mix:
Cash Patients – 67% (Tamilians prefer paying upfront than waiting in TPA queues).
TPAs / Corporates – 22%
Govt Schemes – 11%
4. Financials Overview
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
₹66.6 Cr
₹53.1 Cr
₹60.9 Cr
25.4%
9.3%
EBITDA
₹16.5 Cr
₹12.9 Cr
₹15.4 Cr
27.5%
6.8%
PAT
₹7.54 Cr
₹5.51 Cr
₹4.52 Cr
36.8%
66.8%
EPS (₹)
0.46
0.34
0.28
35.3%
64.3%
Commentary: Revenue growing, profits healthy. But EPS of ₹1.44 (FY25 full year) means the 47.7x P/E looks like Apollo cosplay.
5. Valuation – Fair Value Range
Method 1: P/E
EPS (TTM) = ₹1.44
Fair P/E multiple = 25–30 (regional hospital, not pan-India brand).
Range = ₹36 – ₹43.
Method 2: EV/EBITDA
EV = ₹1,199 Cr, EBITDA = ₹64 Cr.
EV/EBITDA = 18.8x. Fair multiple 10–12 → Value ₹640–₹770 Cr → Per share ₹39 – ₹47.
